The trial revealed a linear correlation between higher tumor burden and anti-PD1 and anti-programmed death ligand (PD-L1) checkpoint inhibitors, explained as the immune system responding to reactivation.
Multiple clinical trials are currently underway examining the possible synergistic effects of combining chemotherapy with immunotherapies for patients with bladder cancer and other metastases.
Bacillus Calmette-Guérin (BCG) is an effective biologic therapy widely used in patients with non-muscle invasive bladder cancer. Sanofi recently announced their intent to discontinue BCG production, leaving Merck…
An increasing number of manufacturers are entering the robotic surgery space. There were over half of a million robot-assisted surgeries in both 2014 and 2015, and that number…
Prolaris is a prostate-specific antigen (PSA) genetic test that analyzes cancer cells of patients diagnosed with prostate cancer. The test determines the aggressiveness of the cancer, helping physicians…
